Journal profile · Pharmacology & Pharmacy
Vascular Pharmacology
ISSN 1537-1891 · eISSN 1879-3649 · Elsevier Inc. · UNITED STATES · Monthly · Founded 2002
Vascular Pharmacology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.71; hybrid open access; APC about USD 3,670; median 68 days to acceptance (98 articles, last 24 months); community-reported acceptance: moderate; 91 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Vascular Pharmacology is published by Elsevier Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Nitric Oxide and Endothelin Effects, Diverse Scientific and Economic Studies and Human auditory perception and evaluation, together about 29.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Vascular Pharmacology is a journal of Vascular Biology and Medicine. We seek to rapidly publish transformative papers, reviews, and perspectives on vascular cells across the disciplines of biochemistry, pharmacology, pathology, physiology, molecular and developmental biology, and clinical medicine using sophisticated tools in genomics/proteomics/transcriptomics, genetics, genome editing, and bioengineering.The journal will consider submissions that address vascular cells in the context of:Atherosclerosis, thrombosis, hemostasisNeurovascular diseasesDiabetes, obesity, and metabolic syndromePulmonary hypertensionCardiovascular toxicity induced by anticancer drugsTransplant arteriopathyVascular aging, repair, and regenerationReperfusion injuryImmunological influence in vascular diseasesMicrovascular dysfunctionPlease check the latest journal related topics and articles on our Twitter account @VasPharma.
From the journal's Aims & Scope
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Joseph MianoPublisher website
Editorial board by country: 9 in mainland China (about 7%); most named United States 85, Italy 13, Mainland China 9, United Kingdom 7, Japan 3 (134 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nitric Oxide and Endothelin EffectsMedicine12.1%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance9.5%
- Human auditory perception and evaluationEngineering7.9%
- Angiogenesis and VEGF in CancerBiochemistry, Genetics and Molecular Biology7%
- Educational Robotics and EngineeringComputer Science6.2%
- Atherosclerosis and Cardiovascular DiseasesImmunology and Microbiology5.3%
- Renin-Angiotensin System StudiesMedicine4.2%
- Eicosanoids and Hypertension PharmacologyBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.71LetPub ·
- Impact factor (publisher)
- 3.7Publisher website ·
- CiteScore 2026-06
- 6.5LetPub ·
- CiteScore (publisher)
- 6.5Publisher website ·
- SJR 2026-06
- 0.99LetPub ·
- SNIP 2026-06
- 0.78LetPub ·
- h-index
- 86LetPub ·
- h-index
- 105OpenAlex ·
- i10-index
- 1,298OpenAlex ·
- 2-year mean citedness
- 2.3OpenAlex ·
- Self-citation rate
- 2.7%LetPub ·
- Share of gold OA articles
- 33.33%LetPub ·
Volume
- Articles per year
- 65LetPub ·
Articles by year OpenAlex count · 3,238 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 107 | 29 | 31 |
| 2025 | 91 | 45 | 282 |
| 2024 | 153 | 47 | 493 |
| 2023 | 96 | 41 | 870 |
| 2022 | 147 | 31 | 981 |
| 2021 | 93 | 34 | 1,289 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
68 daysMedian, submission to acceptance · P25–P75 48 days – 93 days
- Acceptance to online
- median 2 days (98 articles)
- Submission to online
- median 71 days
- Sample
- 98 articles with submission and acceptance dates (158 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 31 daysPublisher website ·
- Submission to acceptance
- 68 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,670 / EUR 3,430 / GBP 2,940 / JPY 455,190 | — | — | |
| Publisher website | USD 3,540 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 5,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Required
- Cover letter
- Required
Article types accepted12, with length limits
- commentaryCommentary about an article published in the journal is allowed. The text should raise a question for clarification, offer an alternative perspective, or explai…main text ≤ 500 words
- commentary and repliesCommentary about an article published in the journal is allowed.Length not stated
- editorialng research trends and clinical issues. Editorials should be approximately 1000–2000 words and contain no more than 10–15 references. Please upload yomain text ≤ 2,000 words · references ≤ 15
- editorialsEditorials provide a forum for opinionated discussions of a topic in the field of vascular pharmacology, or describing historical foundations and influences, em…Length not stated
- lettera discussion of patient cases. Research Letters should be no longer than 1000 words, with no more than 1 figure and 1 table (or 2 tables and nomain text ≤ 1,000 words
- research articleand up-to-date references. The text of research article should be limited to 5000 words including title, abstract, tables, figures, and referencesmain text ≤ 5,000 words
- research articlesOriginal research articles present data that advance the science and clinical practice of vascular pathobiology, medicine, or pharmacology.Length not stated
- research letters to the editorResearch Letters may present original unpublished studies of a more preliminary nature, or a discussion of patient cases.Length not stated
- revieweview or Perspective before submission. Reviews shall have a maximum length of 6,000 words (the word count limit includes title, abstract, tables, figmain text ≤ 6,000 words · abstract ≤ 200 words · figures and tables ≤ 8 · references ≤ 80
- reviewsReviews should provide a balanced synthesis of prior knowledge and new scholarly advances in vascular biology, medicine, or pharmacology.Length not stated
- short communicationeive prioritized and rapid publication. Short Communications are limited to 3000 words and are not subdivided. The paper should contain an abstracmain text ≤ 3,000 words · abstract ≤ 100 words · figures and tables ≤ 6
- short communicationsShort Communications are short papers that present original and significant material for rapid dissemination.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Publishing ethics policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2002
- ISSN
- 1537-1891
- Electronic ISSN
- 1879-3649
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Vascular Pharmacology
What CAS zone is Vascular Pharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Vascular Pharmacology is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Vascular Pharmacology?
The latest impact factor listed by LetPub is 3.71; CiteScore 6.5, h-index 105.
How long does peer review take at Vascular Pharmacology?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 68 days (interquartile range 48–93 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Vascular Pharmacology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 5,000 words; Reference style: Numbered, in order of citation; Highlights: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Vascular Pharmacology based?
Of the 134 board members whose country the journal's board page names, 9 (about 7%) are in mainland China; the countries named most often are United States (85), Italy (13) and Mainland China (9). Counted from the institutions listed on the board page; for reference only.
Which databases index Vascular Pharmacology?
According to LetPub and DOAJ records, Vascular Pharmacology is indexed in SCIE and Scopus.
Is Vascular Pharmacology open access, and what is the APC?
Vascular Pharmacology is a hybrid journal. For open-access publication: APC about USD 3,670.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .